S
S. Saadatmand
Researcher at Erasmus University Medical Center
Publications - 5
Citations - 231
S. Saadatmand is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Mammography & Breast cancer. The author has an hindex of 4, co-authored 5 publications receiving 149 citations.
Papers
More filters
Journal ArticleDOI
MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial
S. Saadatmand,H Amarens Geuzinge,Emiel J. Th. Rutgers,Ritse M. Mann,Diderick B W de Roy van Zuidewijn,H. M. Zonderland,Rob A. E. M. Tollenaar,Marc B. I. Lobbes,Margreet G. E. M. Ausems,Martijne van 't Riet,Maartje J. Hooning,Ingeborg Mares-Engelberts,Ernest J. T. Luiten,Eveline A.M. Heijnsdijk,Cees Verhoef,Nico Karssemeijer,Jan C. Oosterwijk,Inge-Marie Obdeijn,Harry J. de Koning,Madeleine M. A. Tilanus-Linthorst,Carolien H.M. van Deurzen,Claudette E. Loo,Jelle Wesseling,Margrethe Schlooz-Vries,Suzan van der Meij,Wilma E. Mesker,Kristien Keymeulen,Carolien Contant,Eva V. E. Madsen,Linetta B. Koppert,Joost Rothbarth,Wouter B. Veldhuis,Arjen J Witkamp,Eric Tetteroo,Cécile de Monyé,Mandy M van Rosmalen,Jolanda Remmelzwaal,Huub B W Gort,Roelie Roi-Antonides,Martin N. J. M. Wasser,Edith van Druten +40 more
TL;DR: MRI screening detected cancers at an earlier stage than mammography in women with familial risk of breast cancer, and the lower number of late-stage cancers identified in incident rounds might reduce the use of adjuvant chemotherapy and decrease breast cancer-related mortality.
Journal ArticleDOI
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
Xuan-Anh Phi,S. Saadatmand,Geertruida H. de Bock,Ellen Warner,Francesco Sardanelli,Martin O. Leach,Christopher C. Riedl,Isabelle Trop,Maartje J. Hooning,Rodica Mandel,Filippo Santoro,Gek Kwan-Lim,Thomas H. Helbich,Madeleine M. A. Tilanus-Linthorst,Edwin R. van den Heuvel,Nehmat Houssami +15 more
TL;DR: Additional screening sensitivity from mammography above that from MRI is limited in BRCA1 mutation carriers, whereas mammography contributes to screening sensitivity in B RCA2 mutation carrier, especially those ⩽40 years.
Journal ArticleDOI
Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis.
Xuan-Anh Phi,Nehmat Houssami,Maartje J. Hooning,Christopher C. Riedl,Martin O. Leach,Francesco Sardanelli,Ellen Warner,Isabelle Trop,S. Saadatmand,Madeleine M. A. Tilanus-Linthorst,Thomas H. Helbich,Edwin R. van den Heuvel,Harry J. de Koning,Inge-Marie Obdeijn,Geertruida H. de Bock +14 more
TL;DR: In this population of women with strong familial BC risk but without a known gene mutation, in whom BC incidence was high both before and after age 50, adding MRI to mammography substantially increased screening sensitivity but also decreased its specificity.
Journal ArticleDOI
Cost-effectiveness of Breast Cancer Screening with Magnetic Resonance Imaging for Women at Familial Risk
H Amarens Geuzinge,Inge-Marie Obdeijn,Emiel J. Th. Rutgers,S. Saadatmand,Ritse M. Mann,Ritse M. Mann,Jan C. Oosterwijk,Rob A. E. M. Tollenaar,Diderick B W de Roy van Zuidewijn,Marc B. I. Lobbes,Martijne van 't Riet,Maartje J. Hooning,Margreet G. E. M. Ausems,Claudette E. Loo,Jelle Wesseling,Ernest J. T. Luiten,H. M. Zonderland,Cees Verhoef,Eveline A.M. Heijnsdijk,Madeleine M. A. Tilanus-Linthorst,Harry J. de Koning +20 more
TL;DR: This study suggests that MRI screening every 18 months between the ages of 35 and 60 years for women with a family history of breast cancer is cost-effective within the National Institute for Health and Care Excellence threshold for all densities.